Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x91px
Person › Details

Holger Zinke (BRAIN Biotechnology Reserarch and Information Network AG (FSE: BNN))

Zinke, Holger (BRAIN 201507– Supervisory Board Member before CEO)

 

Organisation Organisation BRAIN Biotechnology Reserarch and Information Network AG (FSE: BNN)
  Group BRAIN (Group)
Products Product WHITE BIOTECHNOLOGY
  Product 2 industrial biotechnology
     

BRAIN AG. (7/29/15). "Press Release: BRAIN Panels Decide on Next Steps for the Continuation of the Industrialization Strategy. BRAIN Management Team to Be Enlarged". Zwingenberg.

BRAIN AG announces its next steps concerning the expansion of the company’s industrialization strategy, “BRAIN Agenda 2020”, which has been approved by the management board, supervisory board, and shareholders alike. The steady commitment to this strategy had already permitted a strongly growing group of companies operating in attractive markets to emerge over the past few years. The newly adopted expanded management structures will now form the basis for the company’s evolution in the industrial field.

In the enlarged BRAIN management team, co-founder Dr. Jürgen Eck has taken on the role of chairman and chief executive of BRAIN AG as of July 01, 2015. The long-standing CTO and deputy chairman thus succeeds Dr. Holger Zinke, who transferred to the supervisory board after his election by the general meeting of shareholders on July 08, 2015.

There, he has taken on the office of deputy chairman of the supervisory board following Michael Motschmann (chairman of MIG Verwaltungs AG). Mr. Motschmann, who had lent his support to the company since 2007 as a member of the supervisory board, deserves praise and thanks by the shareholders, the supervisory board and not least the management board of BRAIN for his tireless and committed efforts on the company’s supervisory body.

In addition to his role on the supervisory board, Dr. Zinke will reinforce his activities in the areas of economic and research policy, supporting the implementation of a bio-based economy (“bioeconomy”) in politics, the economy, and the capital market. Furthermore, he will head the newly created Industrial Advisory Panel, which consists of distinguished persons from the fields of economy, research, and politics and which will advise the company in matters of strategy.

In view of the growing operative areas within BRAIN AG, the longstanding heads of the “BioActives” and “Microbial Strain Development” technology units, Dr. Michael Krohn and Dr. Guido Meurer, as well as Dr. Martin Langer, who heads the "Corporate Development" corporate unit and who has been a part of the company for more than 20 years, have been appointed to the management team and granted full power of attorney. Together with the management board and the long-established head of Finance & Controlling, Rudolf Bröcker, they will, in future, be responsible for technology, strategy, business development, finances, and the operational business, in particular for the internationalization of the co-operation business and the extension of the product business.

In light of the development of BRAIN’s business operations, Thomas Kessler (former head of Global Platform Specialties with Merck KGaA) will join BRAIN’s Business Operations unit in order to strengthen it and manage its strategic orientation. The BRAIN Group’s management team was also enlarged by Frank Goebel (former Investment Director/Strategic Investment Group with the Royal Bank of Scotland), who was tasked with the expansion of value chains by means of M&A activities.

"These measures, which were unanimously approved at the last ordinary general meeting, underscore both the shareholders’ and the supervisory board’s emphatic commitment to the industrialization strategy adopted as early as 2010 and sustainably strengthen the group along the way of managing its acquisitions which already have been successfully integrated in the value chains. The newly created "Industrial Advisory Panel" will consolidate the company’s industrial positioning thanks to valuable external expertise,” explains Dr. Ludger Müller, chairman of the supervisory board, on this occasion.

Adds Dr. Jürgen Eck, chairman of BRAIN’s board of management: "The formation of a broader management team at BRAIN, which explicitly also includes the leaders of the company’s subsidiaries in the team, has created an adequate structure for further growth in the cooperation and in the industrial product business alike. The management team is experienced and highly motivated to make essential contributions for BRAIN and for the biological transformation of the target industries."

The shareholders, supervisory board and the board of management have thus set the course for the future development of BRAIN in a trailblazing manner. BRAIN as a company will grow further thanks to experience based on more than 20 years of co-operation with industry partners. At the same time, the company will continue to be active in the markets as an innovation leader across the entire range of biotechnology applications. By implementing the agreed-on strategy,
shareholders and the entire staff of BRAIN will contribute to ensuring that available potentials are harnessed in the long term and that the company will continue to play a leading role when it comes to the road-range biologization of industries.


About BRAIN:

BRAIN AG is an industrial “white” biotech company which discovers and develops novel bioactive natural compounds and proprietary enzymes for its partners and customers in the chemical and pharmaceutical industries, as well as the food and cosmetics industries. With its unique approach to the discovery and production of new biological compounds and biocatalysts, the company achieves creative solutions by harnessing nature’s untapped biodiversity. Its success is built on its proprietary BioArchive comprising millions of genes, proteins and metabolic pathways from microbial isolates and metagenome libraries. Since its foundation in 1993, BRAIN has entered into over 100 strategic collaborations with nearly all the relevant companies within the chemical industry as e.g. BASF, Ciba, Clariant, Evonik, DSM, Genencor, Henkel, Nutrinova, RWE, Sandoz, Schering, Südzucker and Symrise, to name but a few. Currently, BRAIN employs 120 highly skilled personnel.

The industrialization strategy, which was successfully launched in 2010 as the company’s second pillar of operation next to the co-operation business, has been expanded successfully. It permits BRAIN AG to access the BRAIN Group’s entire value chain of different lucrative markets, from the identification of biological solutions and their development to their implementation in the target industries. Currently, the BRAIN Group consists of six companies, all of which operate successfully in the market.

www.brain-biotech.de


Contakt:

B.R.A.I.N
Biotechnology Research
And Information Network AG
Dr. Martin Langer
Unit Head Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
Tel.: +49-(0)-6251-9331-16
Fax.: +49-(0)-6251-9331-11
E-Mail: ml@brain-biotech.de
www.brain-biotech.de

   
Record changed: 2017-04-09

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 650x99px


More documents for Holger Zinke


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

[iito] Business Intelligence – The Elephants Are Coming 560x113px




» top